

Sector update

INDIA

General insurance

Private non-life insurers maintain growth momentum

Nov'20 / FY21-TD Gross Domestic Premium Income (GDPI) for non-life insurers grew 3% / 1.4% YoY of which private non-life insurers grew 9% / 3.8% YoY while PSU insurers witnessed a decline of 4.4% / 1.7% YoY. We observe four trends in non-life insurance premium trends: 1) Strong FY21-TD growth in health premiums led by standalone health insurers (SAHI); (2) high but decelerating trend in Covid-related claims; (3) slowly improving auto registrations; and (4) declining market share of PSU insurers. We reiterate our overweight stance on non-life insurance companies.

Table 1: Non-life GDPI growth trend


	Apr'20	May'20	Jun'20	Jul'20	Aug'20	Sep'20	Oct'20	Nov'20	YTD
SAHI	7.2%	-1.0%	42.5%	40.9%	36.4%	38.1%	32.2%	13.5%	26.6%
Lombard	-9.0%	-19.6%	19.6%	5.4%	11.8%	7.3%	10.2%	7.0%	3.1%
BAGIC	-21.1%	-21.9%	-16.1%	113.3	-9.1%	-53.2%	-5.6%	13.6%	-7.0%
Bharti AXA	-16.3%	-20.0%	3.0%	9.4%	1.6%	6.2%	8.7%	18.4%	2.7%
PSU	-6.3%	-0.5%	5.5%	9.2%	7.7%	-5.4%	-15.2%	-4.4%	-1.7%
Ex-PSU	-14.0%	-14.6%	9.9%	25.7%	12.6%	-5.0%	10.2%	9.0%	3.8%
Overall	-10.6%	-8.8%	8.0%	18.3%	10.4%	-5.2%	-0.4%	3%	1.4%

Source: IRDAI. Note: SAHI – standalone health insurers, ICICIGI – ICICI Lombard; BAGIC – Bajaj General Insurance

Note: For SAHI FY-21TD GDPI we have considered HDFC Ergo Health Insurance GDPI in the calculation and have adjusted HDFC Ergo General insurance GDPI accordingly

Covid claim amount rose by US\$209mn in Aug'20, US\$374mn in Sep'20, US\$305mn in Oct'20 and US\$249mn in Nov'20 – signalling a sign of moderation

Chart 1: Pace of incremental Covid claims has moderated...



Source: Media reports

Chart 2: ...so has Covid claim amount




Table 2: Motor vehicle retail registration data shows PV growth turned positive in Nov'20 while 2Ws continue to exhibit negative trend. However, on MoM basis, PV and 2W have grown 13.5% and 33%, respectively, in Nov'20

(‘000)	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20
Passenger cars	21	32	128	159	175	192	249	282
2W	319	161	795	886	888	1,012	1,043	1,383
CV	20	2	12	21	27	40	47	50

YoY growth	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	YTD
Passenger cars	-91%	-86%	-37%	-23%	-7%	10%	-8%	2.1%	-31%
2W	-76%	-89%	-41%	-37%	-30%	-13%	-27%	-23%	-50%
CV	-59%	-96%	-72%	-55%	-36%	-2%	14%	-33%	-63%

Source: Vahan

Table 3: Non-life insurers GDPI

S.No.	Insurer	Rs mn		Rs mn		Market share FY21-TD (%)
		Nov'20	YoY	FY21-TD	YoY	
1	Acko General Insurance	390	22	2,346	-5.4	0.18
2	Bajaj Allianz General Insurance	8,972	14	82,529	-7.0	6.46
3	Bharti AXA General Insurance	2,637	18	22,164	2.7	1.74
4	Cholamandalam MS General Insurance	3,850	8	27,400	-6.7	2.14
5	DHFL General Insurance	106	29	621	-49.4	0.05
6	Edelweiss General Insurance	164	46	1,336	73.1	0.10
7	Future Generali India Insurance	3,328	-3	23,173	8.6	1.81
8	Go Digit General Insurance Limited	2,567	30	18,650	31.9	1.46
9	HDFC Ergo General insurance	6,706	21	64,438	2.8	6.11
10	ICICI Lombard General Insurance	13,103	7	93,046	3.1	7.28
11	IFFCO Tokio General Insurance	7,072	4	57,308	2.7	4.49
12	Kotak Mahindra General Insurance	456	15	3,289	24.1	0.26
13	Liberty General Insurance Limited	1,253	-5	9,318	-7.8	0.73
14	Magma HDI General Insurance	1,043	-4	7,509	-4.7	0.59
15	National Insurance	11,475	-6	91,340	-9.6	7.15
16	Raheja QBE General Insurance	176	61	1,298	57.1	0.10
17	Reliance General Insurance	5,743	12	57,183	3.8	4.48
18	Royal Sundaram General Insurance	2,258	-6	17,279	-28.6	1.35
19	SBI General Insurance	6,106	-11	47,499	6.8	3.72
20	Shriram General Insurance	1,741	-12	13,817	-13.6	1.08
21	Tata AIG General Insurance	7,128	25	52,934	3.0	4.14
22	The New India Assurance	20,480	7	181,500	1.0	14.21
23	The Oriental Insurance	9,149	-10	82,353	-8.7	6.45
24	United India Insurance	10,563	-25	1,06,697	-2.6	8.35
25	Universal Sompo General Insurance	2,773	11	18,972	12.9	1.49
General Insurers Total		1,29,239	2	10,83,997	-1.3	85.92
26	Aditya Birla Health Insurance	937	27	7,491	64.2	0.59
27	HDFC Ergo Health Insurance	1,564	-7	13,578	-2.8	-
28	ManipalCigna Health Insurance	653	29	4,582	24.5	0.36
29	Max Bupa Health Insurance	1,265	31	9,772	35.8	0.76
30	Religare Health Insurance	1,737	-25	15,326	-1.0	1.20
31	Star Health & Allied Insurance	7,093	30	54,643	42.6	4.28
32	Reliance Health Insurance Limited*	-	-100	-0	-100.2	(0.00)
Stand-alone Pvt Health Insurers		13,248	13	1,05,391	26.6	7.19
33	Agricultural Insurance Company of India Limited	6,572	12	81,882	14.3	6.41
34	ECGC Limited	752	-30	6,161	-13.5	0.48
Specialised PSU Insurers		7,323	5	88,043	11.8	6.89
GRAND TOTAL		1,49,810	2.7	12,77,432	1.4	100.00

Source: IRDAI

Note: For SAHI FY-21TD GDPI we have considered HDFC Ergo Health Insurance GDPI in the calculation and have adjusted HDFC Ergo General insurance GDPI accordingly.

ICICI Securities has received an investment banking mandate from ICICI Lombard General Insurance Company Limited. This update is prepared on the basis of publicly available information.

ICICI Lombard General Insurance Company Limited is a group company (Associate) of ICICI Securities Limited. However, the report and views are based on publicly available information."

In case of industry/sector reports or a report containing multiple stocks, the rating/recommendation for a particular stock may be based on the last released stock specific report for that company."

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)

BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Ansuman Deb, MBA, BE; Ravin Kurwa, CA authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a SEBI registered Research Analyst with SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.